UroGen Pharma (NASDAQ:URGN) – Research analysts at Jefferies Group cut their Q2 2018 earnings per share (EPS) estimates for UroGen Pharma in a research note issued on Wednesday, May 16th. Jefferies Group analyst M. Andrews now expects that the company will post earnings of ($0.90) per share for the quarter, down from their previous forecast of ($0.88). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for UroGen Pharma’s Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.18) EPS, FY2018 earnings at ($3.89) EPS, FY2019 earnings at ($4.57) EPS, FY2020 earnings at ($3.44) EPS, FY2021 earnings at ($2.29) EPS and FY2022 earnings at ($0.03) EPS.
UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, May 15th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.15). The company had revenue of $0.48 million for the quarter.
NASDAQ:URGN opened at $62.04 on Friday. UroGen Pharma has a 1-year low of $61.05 and a 1-year high of $61.50.
A number of institutional investors have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in UroGen Pharma by 1,285.4% in the first quarter. Millennium Management LLC now owns 159,113 shares of the company’s stock worth $7,906,000 after purchasing an additional 147,628 shares in the last quarter. DAFNA Capital Management LLC bought a new position in UroGen Pharma in the first quarter worth about $224,000. ETF Managers Group LLC raised its holdings in UroGen Pharma by 19.2% in the first quarter. ETF Managers Group LLC now owns 8,161 shares of the company’s stock worth $395,000 after purchasing an additional 1,316 shares in the last quarter. Barclays PLC bought a new position in UroGen Pharma in the first quarter worth about $1,242,000. Finally, UBS Group AG raised its holdings in UroGen Pharma by 31.5% in the first quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after purchasing an additional 865 shares in the last quarter. Institutional investors and hedge funds own 53.00% of the company’s stock.
UroGen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.